#Work @WeedConnection

:: Opportunities @WeedConnection ::
:: Contribute Exclusive CannaContent ::
:: Click Here For Submission Guidelines ::
:: Sales, Managers, Interns, Street Team, etc. ::
:: Performance Pay = Commission + Fun ::
:: Click Here For More Information ::

:: International Directory/Managers ::

#Work @WeedConnection

WeedConnection @ Twitter @WeedConnection @ Facebook @WeedConnection @ LinkedIn @WeedConnection @ Foursquare @WeedConnection @ Spotify @WeedConnection @ YouTube @WeedConnection @ Yelp @WeedConnection @ Google+ @WeedConnection @ instaGram



#cOnNeCt @WeedConnection

#Support Your #OG(s)
#LinkUP @WeedConnection .com
:: Subscribe, Follow, Add, Like, Share ::


@RussellRope .com

#Connect @WeedConnection
#Connect @WeedConnection


WeedConnection @ Twitter @WeedConnection @ Facebook @WeedConnection @ LinkedIn @WeedConnection @ Foursquare @WeedConnection @ Spotify @WeedConnection @ YouTube @WeedConnection @ Yelp @WeedConnection @ Google+ @WeedConnection @ instaGram


#NORML #News @WeedConnection

Analysis: Adult-Use Marijuana Sales Yield Over $10 Billion in New Tax Revenue

Washington, DC: State-authorized sales of retail marijuana products have yielded more than $10 billion in new tax revenue, according to an analysis compiled by the Marijuana Policy Project.

"Legalizing cannabis for adults has been a wise investment," authors of the report concluded. "Since 2014 when sales began in Colorado and Washington, legalization policies have provided states a new revenue stream to bolster budgets and fund important services and programs. As of December 2021, states reported a combined total of $10.4 billion in tax revenue from legal, adult-use cannabis sales. In addition to revenue generated for statewide budgets, cities and towns have also generated hundreds of thousands of dollars in new revenue from local adult-use cannabis taxes."

These revenues have been used to fund various state-specific projects, MPP's analysis reported. In Colorado, for instance, over $470 million in cannabis-specific tax revenue has been applied toward public schools. In Washington, some $600 million in revenue has been directed toward public health initiatives, including a fund that provides health insurance to low-income families. In California, over $100 million in revenue has been provided to community investment programs and local nonprofit groups.

In every state permitting adult-use sales, marijuana tax revenues have grown year-over-year.

Full text of the report, "Cannabis Tax Revenue in States that Regulate Cannabis for Adult Use," is available online.


Survey: Many Health Care Professionals Possess a "Poor" Understanding of Cannabis Use for Medical Purposes

Portland, OR: A significant percentage of health care practitioners possess only limited knowledge about the use and efficacy of medical cannabis, according to survey data published in the Journal of the American Association of Nurse Practitioners.

A team of investigators affiliated with the Oregon Health & Science University surveyed 178 health care professionals (physicians, registered nurses, and nurse practitioners) attending a Continuing Medical Education program on the clinical uses of cannabis. Nearly all of the health professionals surveyed were licensed to practice in either California, Oregon, or Washington – three jurisdictions where medical cannabis access has been legally available for more than two decades.

Researchers reported: "This study found that HCPs' [health care professionals] knowledge about the medical risks and benefits of clinical cannabis, although similar among professions, is generally poor and has specific important gaps. Health care professionals scored an average of only 63.2 percent on direct knowledge tests about clinical cannabis, with no significant differences among professions. Attendees scored highest on questions about laws and regulations (85.7 percent). Mean scores for questions related to all other topics, including risks and harms, pharmacology, pain, multiple sclerosis spasticity, and seizures, were all below 70 percent, equivalent to a C grade."

They added, "Despite more than 95 percent of respondents practicing in states (Oregon, Washington, or California) where clinical cannabis had been legal for more than 20 years and recreational cannabis had been legal for at least two years, their knowledge about clinical cannabis was poor. This supports that wide and prolonged availability of cannabis is not sufficient to accomplish provider knowledge and that more education is needed."

Authors concluded, "The findings of this study support that, despite a growing evidence base, and even after many years of legalization, HCPs including APRNs [advance practice registered nurses] have substantial gaps in their knowledge of the potential risks and benefits associated with the use of cannabis for medical purposes."

The study's conclusions are consistent with those of prior surveys of health care professionals in which most doctors and nurses acknowledge that they are insufficiently trained in issues related to the use of cannabis. Separate survey data published in 2020 also reported that fewer than one-in-five patients believe that their primary care providers are sufficiently knowledgeable about cannabis-specific health-related issues.

Full text of the study, "Cannabis for medical purposes: A cross-sectional analysis of health care professionals' knowledge," appears in the Journal of the American Association of Nurse Practitioners.


Analysis: Frequent Cannabis Use Associated with Lower Incidences of Diabetes Among Women

College Station, TX: Women who frequently consume cannabis are less likely to be diagnosed with diabetes mellitus, according to data published in the journal Cannabis and Cannabinoid Research.

Researchers at Texas A&M University assessed the relationship between cannabis use and diabetes in a nationally representative sample of over 15,000 adults.

They reported that women who were frequent cannabis consumers were less than half as likely to be diagnosed with diabetes as compared to female non-users. No differences were observed among women who only consumed cannabis occasionally.

Researchers did not identify a similar inverse relationship among males. They concluded, "Further studies are needed to explore the sex-based heterogeneity-and individual and contextual factors responsible-in the association between cannabis use and diabetes mellitus."

Several previous studies have identified a correlation between frequent cannabis use and lower odds of adult-onset diabetes, while clinical trial data has shown that the administration of THCV is associated with improved glycemic control in type 2 diabetics.

Full text of the study, "Sex differences in the association between cannabis use and diabetes mellitus among US adults: The National Health and Nutritional Examination Survey, 2013-2018," appears in Cannabis and Cannabinoid Research.


Study: Labeling of Commercially Available CBD Products Often Inaccurate

Madison, WI: Commercially available CBD-infused products typically contain percentages of cannabidiol that differ significantly from the information provided on their labels, according to data published in the journal Epilepsy & Behavior.

A team of investigators affiliated with the University of Wisconsin, School of Pharmacy performed laboratory analyses on a variety of commercially available CBD products, including infused oils, beverages, and edibles.

Consistent with numerous other analyses of unregulated, commercially available CBD-branded products, investigators reported that the percentage of CBD available in many of the products tested "varies largely from their label claims." CBD-infused beverage products were most likely to contain CBD percentages that differed from their labels.

More than three years following the passage of federal legislation legalizing hemp production, the US Food and Drug Administration (FDA) has yet to promulgate rules regulating the marketing and sale of commercial products containing hemp-derived CBD. Speaking in October at the National Industrial Hemp Business Summit in Washington, DC, FDA representative Gail Sipes said that the agency cannot move forward with regulations without more data on the safety of CBD products. At that time, she reiterated the agency's position that companies that market CBD-infused products as either food products or as dietary supplements are violating the Food, Drugs, and Cosmetics Act.

In a report provided by the FDA to Congress in 2020, the agency said that regulating over-the-counter CBD products presents a unique challenge because the substance is already available as a FDA-approved medicine (Epidiolex).

NORML and other groups have consistently urged the FDA to provide regulatory guidelines overseeing the production, testing, labeling, and marketing of hemp-derived CBD products.

Full text of the study, "Analysis of cannabidiol (CBD) and THC in nonprescription consumer products: Implications for patients and practitioners," appears inEpilepsy & Behavior.

#NORML #News @WeedConnection

WeedConnection @ Twitter @WeedConnection @ Facebook @WeedConnection @ LinkedIn @WeedConnection @ Foursquare @WeedConnection @ Spotify @WeedConnection @ YouTube

#LeGaLiZe >< #MLKJDay @WeedConnection

#HeMPY #HoLiDaZe @WeedConnection

#MLKJ quotes make great points for legalization of marijuana and much more:

"Law and order exist for the purpose of establishing justice and when they fail in this purpose they become the dangerously structured dams that block the flow of social progress." The drug war has failed. Put our resources to better use.

"Injustice anywhere is a threat to justice everywhere." Local legalization is not complete justice. Medical and legal states are still in danger until there is federal reform.

"The ultimate tragedy is not the oppression and cruelty by the bad people but the silence over that by the good people." Do something for the cause.

"The time is always right to do what is right." Share this post, get informed, and support activist organizations.


#FollowFriday @RussellRope #OG @WeedConnection

* New Show NQ @TheTrueOGReport *

* READ & Click & READ & Click *

:: Creator @ WC @ RR Productions ::
:: Follow @RussellRope For Updates ::

#OG @RussellRope #Creator @WeedConnection

:: Join The Revolution ::
:: Read & Take Action ::
:: True OG Stories @ RR ::
:: SUPREME #LegalTrillOG ::


:: Media Marketing Services @ RRP ::

:: Connect | ADVERTISE | Work | Submit ::

:: Subscribe | Follow | Share | Like | Support ::

:: #FreeTheWeed @WeedConnection ::

WeedConnection @ Twitter @WeedConnection @ Facebook @WeedConnection @ LinkedIn @WeedConnection @ Foursquare @WeedConnection @ Spotify @WeedConnection @ YouTube @WeedConnection @ Yelp @WeedConnection @ Google+ @WeedConnection @ instaGram



New directory with maps etc. in development….
LiMiTed oFFeR: dOuBLe DuRAtiON oF NeW LiSTiNGs (wHiLe sTiLL iN DeV mOde)
oR 10% DiScOuNt :: Select You Plan @ [click here]

Ask about our current promotion, which is a free listing with purchase of any other service @WeedConnection. Recently started rebuilding our global database and added a new/temp delivery section to our directory. Send us an email to submit any current information. Click here for listing and advertising information. The directory is a huge project that requires maintenance. We still have big plans for future development and production. Join(t) the team as a regional manager, college intern, street team member, or click here for a list of other open positions. Support, subscribe, follow, share, like, and mention growing cannabis business @WeedConnection

#iNTERNATiONAL #Directory

WeedConnection @ Twitter @WeedConnection @ Facebook @WeedConnection @ LinkedIn @WeedConnection @ Foursquare @WeedConnection @ Spotify @WeedConnection @ YouTube @WeedConnection @ Yelp @WeedConnection @ Google+ @WeedConnection @ instaGram


#NORML #News @WeedConnection

Analysis: Public Interest in Delta-8 Products Rising in States Where Cannabis Remains Criminalized

San Diego, CA: The popularity of unregulated products containing delta-8 THC is far greater in states where cannabis is illegal than it is in jurisdictions where it has been legalized, according to an analysis published in The International Journal of Drug Policy.

Researchers at the University of California, San Diego analyzed Internet users' interest in delta-8 THC products in all 50 states. They found that online searches for delta-8 THC products grew significantly in the years 2019 and 2020 and that public interest "was particularly high in US states that restricted delta-9 THC use."

Although delta-8 THC occurs organically in the cannabis plant, it is only produced in nominal quantities. By contrast, the elevated quantities of delta-8 THC found in grey market products are the result of a chemical synthesis during which manufacturers convert hemp-derived CBD to delta-8 THC. Manufacturers engaged in synthesizing delta-8 THC are not regulated and often use potentially dangerous household products to facilitate this process. Lab analyses of unregulated delta-8 products have consistently found them to contain lower levels of the compound than advertised on the products' labels. Some products have also been found to possess heavy metal contaminants and unlabeled cutting agents.

In October, NORML issued a report on delta-8 THC and other novel, synthetically derived cannabinoids that cautioned consumers to avoid these unregulated products because they are untested and may contain impurities.

According to survey results published in The Journal of Cannabis Research, consumers of delta-8 THC products typically use them for relaxation and pain management. Consumers often report the effects of these products to be less potent than those of whole-plant cannabis and of a shorter duration.

Full text of the study, "Public interest in delta-8 THC increased in US states that restricted delta-9 THC use," appears in The International Journal of Drug Policy. Full text of the study - "Delta-8-THC: Delta-9-THC's nicer younger sibling?" - appears in The Journal of Cannabis Research.

Review: Minor Cannabinoids Acknowledged to Possess Therapeutic Properties

Columbia, South Carolina: Numerous minor cannabinoids found in the cannabis plant possess therapeutic properties that may hold clinical significance, according to a review paper published in the journal Frontiers of Pharmacology.

A team of US investigators affiliated with the University of South Carolina and Doane University in Nebraska summarized data on the potential therapeutic applications of a number of secondary cannabinoids, including CBN (cannabinol), CBC (cannabichromine), cannabigerol (CBG), and tetrahydrocannabivarin (THCV). Most of the research available on these compounds has thus far been limited to preclinical studies.

Specifically, authors highlighted the analgesic and anti-inflammatory properties of various ancillary cannabinoids, including CBG, CBC, THCV, and CBN.

They acknowledged that CBN also "shows promise as an antibacterial agent and [as] an appetite stimulant," but cautioned that it has shown inconsistent results as a sleep aid.

Several of these minor cannabinoids, such as CBG and CBC, also possess anti-cancer properties, while THCV "regulates blood glucose levels, suggesting it might be useful in weight reduction and treating diabetes." THCV has also demonstrated anti-epileptic and neuroprotective properties.

Another cannabinoid highlighted by the authors, cannabidivarin (CBDV) possesses anti-seizure activity and may possess therapeutic utility in the treatment of autism, muscular dystrophy, and as an anti-emetic agent.

A number of these minor cannabinoids have "also shown promise in the treatment of skin disorders," investigators reported.

Authors also highlighted the promise of various cannabinoid acids (e.g., CBDA, CBGA, and THCA). Specifically, they acknowledged that CBGA "may play a role in controlling diabetes mellitus and preventing the cardiovascular complications that can accompany Type 2 diabetes," whereas THCA has been shown to mitigate liver fibrosis in animals.

"Minor cannabinoids and their chemical homologs offer the potential medicinal benefits of D9-THC without adverse effects," authors concluded. "Future studies will need to evaluate the risk versus benefit of these and other minor cannabinoids when compared to D9-THC and traditional analgesic drugs."

Full text of the study, "Minor cannabinoids: Biosynthesis, molecular pharmacology and potential therapeutic uses," appears inFrontiers of Pharmacology.

#NORML #News @WeedConnection

WeedConnection @ Twitter @WeedConnection @ Facebook @WeedConnection @ LinkedIn @WeedConnection @ Foursquare @WeedConnection @ Spotify @WeedConnection @ YouTube